Genentech, MedImmune end patent rift over Synagis

06/11/2008 | Bloomberg Businessweek · TheStreet.com

Genentech and MedImmune have reached an agreement to resolve a patent dispute over motavizumab and Synagis, a respiratory drug. The settlement allows MedImmune -- a unit of AstraZeneca PLC -- to receive licenses for selected pipeline products under a patent Genentech co-owns with City of Hope National Medical Center.

View Full Article in:

Bloomberg Businessweek · TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care